Tag: Drugs
Search News
New phase III clinical trial using combination therapy extends survival in triple-negative breast cancer
22nd October 2018
Research provides new hope for people with an aggressive type of breast cancer.
Read more
Immunotherapy shows promise for patients with metastatic triple-negative breast cancer
17th October 2018
Immunotherapy has been shown to confer an encouraging survival benefit in patients with metastatic triple-negative breast cancer (mTNBC).
Read more
Blood Cancer Awareness Month 2018
28th September 2018
Blood Cancer Awareness Month takes place every September to raise awareness of the challenges faced by those living with blood cancer. In the UK, blood cancer is the fifth most common cancer, with 240,000 people living with the disease and 38,000 people being diagnosed with a type of blood cancer each year.
Read more
World Cancer Research Day 2018
24th September 2018
The 24th September is World Cancer Research Day- a day dedicated to raising awareness of the importance of cancer research. Thanks to a united effort by researchers from around the world, cancer survival rates have doubled in the last 40 years, and 50% of those diagnosed with cancer now survive.
Read more
Study links widely-used drug azathioprine to skin cancers
14th September 2018
A drug used to treat inflammatory bowel disease and arthritis, and prevent organ rejection in transplant patients, has been identified as an important contributor to skin cancer development in a study by researchers from Queen Mary University of London, including our Barts Cancer Research UK Centre (BCC) Bioinformatics team, the University of Dundee and the Wellcome Sanger Institute.
Read more
BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials
15th June 2018
Professors Peter Schmid and Thomas Powles attended this year’s ASCO Annual Meeting, which took place from 1st-5th June in Chicago. Prof Schmid, presented data from the PAKT trial- a trial investigating the addition of a novel drug called AZD5363 to a standard chemotherapy regimen as a treatment for triple-negative breast cancer (TNBC). Prof Powles presented results from the ABACUS trial, which is investigating the efficacy and safety of a drug called atezolizumab administered prior to cystectomy in muscle invasive bladder cancer. The ABACUS trial was selected as one of the highlights of this year’s meeting.
Read more